To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change From Baseline in Abdominal Pain at Its Worst on a NRS Through the Treatment Period
Timeframe: Baseline, up to Week 12 (end of the Treatment Period)
Percentage of Participants Who Were 6/12 Week Abdominal Pain 30% Change Responders
Timeframe: Baseline through Week 12